According to a recent LinkedIn post from AMT Medical, the company is bringing in Geert van Gansewinkel as its new Chief Executive Officer. The post highlights his prior experience leading GATT Technologies through CE Mark and U.S. FDA approval and ultimately to an acquisition by Johnson & Johnson.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests this leadership change is intended to support advancement of AMT Medical’s ELANA® Heart Bypass System toward key regulatory milestones. Founder and former CEO Rutger Tulleken is described as continuing with the company as a Strategic Advisor, which may help maintain continuity in clinical collaborations and innovation.
The post emphasizes an ongoing mission to transform coronary bypass surgery into a minimally invasive, reproducible procedure accessible globally. For investors, this leadership transition, combined with a stated focus on regulatory progress, could signal a more execution-oriented phase that may influence timelines to market, partnering prospects, and potential strategic interest from larger MedTech companies.